CB2 cannabinoid receptor-mediated peripheral antinociception

T. Philip Malan, Mohab M. Ibrahim, Hongfeng Deng, Qian Liu, Heriberto P. Mata, Todd W Vanderah, Frank Porreca, Alexandros Makriyannis

Research output: Contribution to journalArticle

319 Citations (Scopus)

Abstract

Cannabinoid receptor agonists diminish responses to painful stimuli. Extensive evidence implicates the CB1 receptor in the production of antinociception. However, the capacity of CB2 receptors, which are located outside the central nervous system (CNS), to produce antinociception is not known. Using AM1241, a CB2 receptor-selective agonist, we demonstrate that CB2 receptors produce antinociception to thermal stimuli. Injection of AM1241 in the hindpaw produced antinociception to a stimulus applied to the same paw. Injection of an equivalent dose of AM1241 into the paw contralateral to the side of testing did not. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630, but not by the CB1 receptor-selective antagonist AM251. AM1241 also produced antinociception when injected systemically (intraperitoneally). The antinociceptive actions of systemic AM1241 were blocked by injection of AM630 into the paw where the thermal stimulus was applied, but not the contralateral paw. These findings demonstrate the local, peripheral nature of CB2 cannabinoid antinociception. AM1241 did not produce the CNS cannabinoid effects of hypothermia, catalepsy, inhibition of activity or impaired ambulation, while this tetrad of effects was produced by the mixed CB1/CB2 receptor agonist WIN55,212-2. Peripheral antinociception without CNS effects is consistent with the peripheral distribution of CB2 receptors. CB2 receptor agonists may have promise clinically for the treatment of pain without CNS cannabinoid side effects.

Original languageEnglish (US)
Pages (from-to)239-245
Number of pages7
JournalPain
Volume93
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Cannabinoid Receptor CB2
Cannabinoid Receptor CB1
Cannabinoids
Central Nervous System
Injections
Hot Temperature
Cannabinoid Receptor Agonists
Catalepsy
AM 1241
Hypothermia
Walking
Pain

Keywords

  • Antagonists
  • Cannabinoid receptor
  • CB receptor

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

Malan, T. P., Ibrahim, M. M., Deng, H., Liu, Q., Mata, H. P., Vanderah, T. W., ... Makriyannis, A. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain, 93(3), 239-245. https://doi.org/10.1016/S0304-3959(01)00321-9

CB2 cannabinoid receptor-mediated peripheral antinociception. / Malan, T. Philip; Ibrahim, Mohab M.; Deng, Hongfeng; Liu, Qian; Mata, Heriberto P.; Vanderah, Todd W; Porreca, Frank; Makriyannis, Alexandros.

In: Pain, Vol. 93, No. 3, 2001, p. 239-245.

Research output: Contribution to journalArticle

Malan, TP, Ibrahim, MM, Deng, H, Liu, Q, Mata, HP, Vanderah, TW, Porreca, F & Makriyannis, A 2001, 'CB2 cannabinoid receptor-mediated peripheral antinociception', Pain, vol. 93, no. 3, pp. 239-245. https://doi.org/10.1016/S0304-3959(01)00321-9
Malan, T. Philip ; Ibrahim, Mohab M. ; Deng, Hongfeng ; Liu, Qian ; Mata, Heriberto P. ; Vanderah, Todd W ; Porreca, Frank ; Makriyannis, Alexandros. / CB2 cannabinoid receptor-mediated peripheral antinociception. In: Pain. 2001 ; Vol. 93, No. 3. pp. 239-245.
@article{7571180e96114751bf052acad8360de4,
title = "CB2 cannabinoid receptor-mediated peripheral antinociception",
abstract = "Cannabinoid receptor agonists diminish responses to painful stimuli. Extensive evidence implicates the CB1 receptor in the production of antinociception. However, the capacity of CB2 receptors, which are located outside the central nervous system (CNS), to produce antinociception is not known. Using AM1241, a CB2 receptor-selective agonist, we demonstrate that CB2 receptors produce antinociception to thermal stimuli. Injection of AM1241 in the hindpaw produced antinociception to a stimulus applied to the same paw. Injection of an equivalent dose of AM1241 into the paw contralateral to the side of testing did not. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630, but not by the CB1 receptor-selective antagonist AM251. AM1241 also produced antinociception when injected systemically (intraperitoneally). The antinociceptive actions of systemic AM1241 were blocked by injection of AM630 into the paw where the thermal stimulus was applied, but not the contralateral paw. These findings demonstrate the local, peripheral nature of CB2 cannabinoid antinociception. AM1241 did not produce the CNS cannabinoid effects of hypothermia, catalepsy, inhibition of activity or impaired ambulation, while this tetrad of effects was produced by the mixed CB1/CB2 receptor agonist WIN55,212-2. Peripheral antinociception without CNS effects is consistent with the peripheral distribution of CB2 receptors. CB2 receptor agonists may have promise clinically for the treatment of pain without CNS cannabinoid side effects.",
keywords = "Antagonists, Cannabinoid receptor, CB receptor",
author = "Malan, {T. Philip} and Ibrahim, {Mohab M.} and Hongfeng Deng and Qian Liu and Mata, {Heriberto P.} and Vanderah, {Todd W} and Frank Porreca and Alexandros Makriyannis",
year = "2001",
doi = "10.1016/S0304-3959(01)00321-9",
language = "English (US)",
volume = "93",
pages = "239--245",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - CB2 cannabinoid receptor-mediated peripheral antinociception

AU - Malan, T. Philip

AU - Ibrahim, Mohab M.

AU - Deng, Hongfeng

AU - Liu, Qian

AU - Mata, Heriberto P.

AU - Vanderah, Todd W

AU - Porreca, Frank

AU - Makriyannis, Alexandros

PY - 2001

Y1 - 2001

N2 - Cannabinoid receptor agonists diminish responses to painful stimuli. Extensive evidence implicates the CB1 receptor in the production of antinociception. However, the capacity of CB2 receptors, which are located outside the central nervous system (CNS), to produce antinociception is not known. Using AM1241, a CB2 receptor-selective agonist, we demonstrate that CB2 receptors produce antinociception to thermal stimuli. Injection of AM1241 in the hindpaw produced antinociception to a stimulus applied to the same paw. Injection of an equivalent dose of AM1241 into the paw contralateral to the side of testing did not. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630, but not by the CB1 receptor-selective antagonist AM251. AM1241 also produced antinociception when injected systemically (intraperitoneally). The antinociceptive actions of systemic AM1241 were blocked by injection of AM630 into the paw where the thermal stimulus was applied, but not the contralateral paw. These findings demonstrate the local, peripheral nature of CB2 cannabinoid antinociception. AM1241 did not produce the CNS cannabinoid effects of hypothermia, catalepsy, inhibition of activity or impaired ambulation, while this tetrad of effects was produced by the mixed CB1/CB2 receptor agonist WIN55,212-2. Peripheral antinociception without CNS effects is consistent with the peripheral distribution of CB2 receptors. CB2 receptor agonists may have promise clinically for the treatment of pain without CNS cannabinoid side effects.

AB - Cannabinoid receptor agonists diminish responses to painful stimuli. Extensive evidence implicates the CB1 receptor in the production of antinociception. However, the capacity of CB2 receptors, which are located outside the central nervous system (CNS), to produce antinociception is not known. Using AM1241, a CB2 receptor-selective agonist, we demonstrate that CB2 receptors produce antinociception to thermal stimuli. Injection of AM1241 in the hindpaw produced antinociception to a stimulus applied to the same paw. Injection of an equivalent dose of AM1241 into the paw contralateral to the side of testing did not. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630, but not by the CB1 receptor-selective antagonist AM251. AM1241 also produced antinociception when injected systemically (intraperitoneally). The antinociceptive actions of systemic AM1241 were blocked by injection of AM630 into the paw where the thermal stimulus was applied, but not the contralateral paw. These findings demonstrate the local, peripheral nature of CB2 cannabinoid antinociception. AM1241 did not produce the CNS cannabinoid effects of hypothermia, catalepsy, inhibition of activity or impaired ambulation, while this tetrad of effects was produced by the mixed CB1/CB2 receptor agonist WIN55,212-2. Peripheral antinociception without CNS effects is consistent with the peripheral distribution of CB2 receptors. CB2 receptor agonists may have promise clinically for the treatment of pain without CNS cannabinoid side effects.

KW - Antagonists

KW - Cannabinoid receptor

KW - CB receptor

UR - http://www.scopus.com/inward/record.url?scp=0034886018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034886018&partnerID=8YFLogxK

U2 - 10.1016/S0304-3959(01)00321-9

DO - 10.1016/S0304-3959(01)00321-9

M3 - Article

C2 - 11514083

AN - SCOPUS:0034886018

VL - 93

SP - 239

EP - 245

JO - Pain

JF - Pain

SN - 0304-3959

IS - 3

ER -